Clinical trial
An Observational Study of Enzyme Replacement Therapy-Naïve and Agalsidase Beta-Treated Fabry Disease Patients With GLA IVS4 919 G>A Mutation in Taiwan
NCT06052800 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Observational Study of Enzyme Replacement Therapy-Naïve and Agalsidase Beta-Treated Fabry Disease Patients With GLA IVS4 919 G>A Mutation in Taiwan
- Lead sponsor
- Sanofi
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- September 13, 2023
- Completion date
- November 6, 2026
- Enrollment
- 78 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.